專家對肝細胞癌當前治療的見解：臨床和分子方法以及進展

StephenW

專家對肝細胞癌當前治療的見解：臨床和分子方法以及進展的瓶頸


     全文
     指標
     獲得許可
     引用這篇文章

作者 Shannon AH、Ruff SM、Pawlik TM

2022 年 9 月 20 日收到

接受出版 2022 年 11 月 18 日

2022 年 12 月 7 日出版 2022 年卷：9 頁 1247-1261

DOI https://doi.org/10.2147/JHC.S383922

檢查抄襲是

單一匿名同行評審

同行評審意見 3

批准出版的編輯：David Gerber 博士
文章的 altmetric 得分為 3
下載文章 [PDF]


亞歷山大 H 香農、薩曼莎 M 拉夫、蒂莫西 M 帕利克

美國俄亥俄州哥倫布市俄亥俄州立大學韋克斯納醫學中心外科腫瘤外科

通信：Timothy M Pawlik，外科學系，Urban Meyer III 和 Shelley Meyer 癌症研究主席，外科學、腫瘤學、衛生服務管理和政策教授，俄亥俄州立大學韋克斯納醫學中心，395 W. 12th Ave.， Suite 670, Columbus, OH, USA，電話 +1 614 293 8701，傳真 +1 614 293 4063，電子郵件 [email protected]

摘要：肝細胞癌（HCC）是一種原發性肝臟腫瘤，通常發生在慢性肝病/肝硬化的情況下。 HCC 的治療方式已經發展，並且鑑於治療方案的多樣性，需要外科、內科、放射腫瘤學、肝病學和介入放射學的多學科方法。 在過去十年中，關於 HCC，尤其是晚期疾病的治療取得了多項進展。 切除和移植仍然是基本的根治性治療選擇。 對於不適合根治性治療的患者，HCC 全身治療的分子和細胞方法已取得令人振奮的進展，包括免疫療法和酪氨酸激酶抑製劑。 儘管晚期 HCC 的預後仍然很差，但治療的設備已經增加，並且可以通過這些治療獲得寶貴的生命年限。 雖然早期疾病的主要治療方式仍然是切除術，但多模式免疫療法已成為晚期疾病的一線治療方法。 我們在此回顧了與 HCC 治療相關的不同臨床和分子治療方式，並提供了對 HCC 治療未來方向的見解。 我們強調如何需要研究和進展才能進入分子和細胞治療的新時代。

Keywords: 肝細胞癌, 目前的治療

StephenW

Expert Insights on Current Treatments for Hepatocellular Carcinoma: Clinical and Molecular Approaches and Bottlenecks to Progress
      

    Fulltext
    Metrics
    Get Permission
    Cite this article

Authors Shannon AH, Ruff SM, Pawlik TM 

Received 20 September 2022

Accepted for publication 18 November 2022

Published 7 December 2022 Volume 2022:9 Pages 1247—1261

DOI https://doi.org/10.2147/JHC.S383922

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Editor who approved publication: Dr David Gerber
Article has an altmetric score of 3
Download Article [PDF] 


Alexander H Shannon, Samantha M Ruff, Timothy M Pawlik

Department of Surgery, Division of Surgical Oncology, The Ohio State University Wexner Medical Center, Columbus, OH, USA

Correspondence: Timothy M Pawlik, Department of Surgery, The Urban Meyer III and Shelley Meyer Chair for Cancer Research, Professor of Surgery, Oncology, Health Services Management and Policy, The Ohio State University, Wexner Medical Center, 395 W. 12th Ave., Suite 670, Columbus, OH, USA, Tel +1 614 293 8701, Fax +1 614 293 4063, Email [email protected]

Abstract: Hepatocellular carcinoma (HCC) is a primary liver tumor that typically occurs in the setting of chronic liver disease/cirrhosis. Treatment modalities for HCC have evolved and given the variety of treatment options, a multi-disciplinary approach requiring input from surgical, medical, and radiation oncology, hepatology, and interventional radiology is necessary. Multiple advances have been made over the last decade regarding treatment of HCC, especially advanced disease. Resection and transplantation remain as cornerstone curative-intent treatment options. For patients who are not candidates for curative-intent therapy, exciting progress has been made in molecular and cellular approaches to systemic therapy for HCC including immunotherapies and tyrosine kinase inhibitors. Although the prognosis for advanced HCC remains poor, the armamentarium of therapies has increased, and valuable years of life can be gained with these therapies. While the main therapeutic modality for early-stage disease remains resection, multimodal immunotherapy has emerged as first-line treatment for advanced disease. We herein review different clinical and molecular treatment modalities related to the treatment of HCC, as well as provide insights into future directions for HCC treatment. We highlight how research and progress are needed to move into a new era of molecular and cellular treatments.

Keywords: hepatocellular carcinoma, current treatments

StephenW

https://www.dovepress.com/getfile.php?fileID=85968